US 12,129,292 B2
Anti-tumor necrosis factor (TNF) antibodies and compositions thereof
Kristopher Barnthouse, Pottstown, PA (US); Subinay Ganguly, Newtown, PA (US); Maarten Groeneveld, Oegstgeest (NL); Manuel Lopez, Devon, PA (US); Michael Nedved, Downingtown, PA (US); and Kevin D. Smith, Philadelphia, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Appl. No. 17/438,657
Filed by Janssen Biotech, Inc., Horsham, PA (US)
PCT Filed Feb. 26, 2020, PCT No. PCT/IB2020/051637
§ 371(c)(1), (2) Date Sep. 13, 2021,
PCT Pub. No. WO2020/183271, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/818,305, filed on Mar. 14, 2019.
Prior Publication US 2022/0153829 A1, May 19, 2022
Int. Cl. C07K 16/24 (2006.01)
CPC C07K 16/241 (2013.01) [C07K 2317/14 (2013.01); C07K 2317/33 (2013.01); C07K 2317/41 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
 
1. Anti-TNF antibodies comprising: (i) a heavy chain comprising an amino acid sequence of SEQ ID NO:38; and (ii) a light chain comprising an amino acid sequence of SEQ ID NO:37, wherein the oligosaccharide profile of the anti-TNF antibodies comprises total neutral oligosaccharide species>99.0% and total charged oligosaccharide species<1.0%.